Zentalis Pharmaceuticals, Inc.
ZNTL
$1.60
-$0.03-1.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -210.28M | -271.69M | -213.34M | -179.28M | -194.65M |
| Total Depreciation and Amortization | 1.06M | 1.23M | 1.29M | 1.31M | 1.34M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 46.10M | 85.25M | 24.79M | 5.41M | 14.10M |
| Change in Net Operating Assets | -20.91M | 747.00K | -16.54M | 804.00K | 12.84M |
| Cash from Operations | -151.09M | -151.52M | -170.86M | -171.76M | -166.38M |
| Capital Expenditure | 0.00 | -181.00K | -221.00K | -394.00K | -485.00K |
| Sale of Property, Plant, and Equipment | 569.00K | 70.00K | 65.00K | 65.00K | 65.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 150.81M | 155.60M | 176.72M | 102.55M | -63.06M |
| Cash from Investing | 151.38M | 155.49M | 176.56M | 102.22M | -63.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 281.00K | 290.00K | 349.00K | 349.00K | 566.00K |
| Repurchase of Common Stock | 0.00 | 0.00 | -241.00K | -241.00K | -241.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 281.00K | 290.00K | 108.00K | 108.00K | 325.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 569.00K | 4.26M | 5.81M | -69.43M | -229.53M |